Table 2 Characteristics at diagnosis of NHL in HIV-positive patients
From: Prognostic factors in HIV-positive patients with non-Hodgkin lymphoma: a Peruvian experience
| Characteristics | N (hn/ph) | Art-naive | Art-exposed | Total |
|---|---|---|---|---|
| CD4 T cells < 100 (cells/mm3) | 47 (34/13) | 19 (55.88%) | 5 (38.46%) | 24 (51.06%) |
| HIV-RNA > 400 (copies/mL) | 47 (34/13) | 23 (67.65%) | 7 (53.85%) | 30 (63.83%) |
| LDH > 330 (mg /dL) | 47 (34/13) | 31 (91.18%) | 12 (92.31%) | 43 (91.49%) |
| Hemoglobin < 10 (g/L) | 47 (34/13) | 7 (20.59%) | 7 (53.85%) | 14 (29.79%) |
| WBC (× 109/L; mean +/− SD) | 46 (34/12) | 7.09 ± 0.87 | 5.69 ± 0.86 | 6.73 ± 0.68 |
| Lymphocytes (× 109/L; mean +/− SD) | 45 (34/11) | 20.49 ± 2.26 | 25.73 ± 4.21 | 21.77 ± 1.99 |
| Albumin< 3 (U/L) | 47 (34/13) | 8 (23.53%) | 3 (23.08%) | 11 (23.4%) |
| AST (IU/L; mean +/− SD) | 47 (34/13) | 70.68 ± 13.71 | 36.42 ± 5.64 | 61.11 ± 10.24 |
| Presence of B symptoms | 47 (34/13) | 16 (47.06%) | 5 (38.46%) | 21 (44.68%) |
| Ki67 (%) | 36 (27/9) | 23 (85.18%) | 9 (100%) | 32 (88.88%) |
| Tumor stage III-IV | 47 (34/13) | 7 (20.59%) | 6 (46.15%) | 13 (27.66%) |
| BM Involvement | 42 (32/10) | 4 (12.5%) | 1 (10%) | 5 (10.64%) |
| ECOG≥ 2 | 47 (34/13) | 11 (32.35%) | 4 (30.77%) | 15 (31.91%) |
| HIV SCORE ≥ 2 | 47 (34/13) | 23 (67.65%) | 6 (46.15%) | 29 (61.07%) |
| IPI ≥ 3 | 47 (34/13) | 18 (52.94%) | 5 (38.46%) | 23 (48.93%) |
| TYPE OF NHL | 47 (34/13) | |||
| DLBC | 21 (61.76%) | 9 (69.23%) | 30 (63.83%) | |
| Burkitts | 5 (14.7%) | 2 (15.38%) | 7 (14.89%) | |
| MALT | 2 (5.88%) | 0 | 2 (4.26%) | |
| Anaplastic | 6 (17.65%) | 2 (15.38%) | 8 (17.02%) |